Cargando…
Melatonin levels in the Alzheimer’s disease continuum: a systematic review
BACKGROUND: The search for new Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and blood biomarkers with potential pathophysiological and clinical relevance continues, as new biomarkers might lead to improved early and differential diagnosis, monitoring of disease progression and might even ident...
Autores principales: | Nous, Amber, Engelborghs, Sebastiaan, Smolders, Ilse |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903801/ https://www.ncbi.nlm.nih.gov/pubmed/33622399 http://dx.doi.org/10.1186/s13195-021-00788-6 |
Ejemplares similares
-
Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer’s Disease but Are Not Correlated with Cognitive Decline
por: Nous, Amber, et al.
Publicado: (2021) -
Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review
por: De Roeck, Ellen Elisa, et al.
Publicado: (2019) -
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
por: Bjerke, Maria, et al.
Publicado: (2018) -
Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease
por: Vande Vyver, Maxime, et al.
Publicado: (2022) -
Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
por: Temmerman, Joke, et al.
Publicado: (2023)